摘要
目的探讨化疗联合唑来膦酸治疗肺癌骨转移的临床效果。方法将收治的64例肺癌骨转移患者,随机分为对照组和观察组,对照组患者采用诺维本联合顺铂(NP)方案治疗,观察组患者在对照组的基础上加用唑来膦酸治疗。比较两组患者的疼痛缓解情况,活动能力改善情况,骨病灶改善情况,生存质量改善情况及不良反应发生情况。结果观察组患者疼痛总缓解率、活动能力恢复总有效率、骨病灶疗效总有效率和生存质量改善率(84.4%、84.4%、68.8%和81.3%)显著高于对照组(53.1%、56.3%、50.0%和46.9%),差异有统计学意义(P<0.05)。两组患者不良反应发生情况差异无统计学意义(P>0.05)。结论化疗联合唑来膦酸用于治疗肺癌骨转移,可显著减轻骨痛等相关事件,显著改善患者的生活质量及活动能力,不良反应少,使用方便,值得临床推广应用。
Objective To explore the clinical effect of the chemotherapy combined zoledronic acid for treatment of bone metastasis of lung cancer. Methods 64 cases of lung cancer patients with bone metastases were randomly divided into control group and observation group. The Control group adopted the NP chemotherapy treatment,and the observation group added zoledronic acid treatment. The situation of pain relief,the activity ability recovery,the improvement of focal bone disease curative effect,improvement of quality of life and adverse reactions were compared. Results The rate of total pain relief,activity recovery,focal bone disease curative effect and improvement of quality of life of observation group（ 84. 4%,84. 4%, 68. 8% and 81. 3% respectively） is significantly higher than those of the control group（ 53. 1%,56. 3%, 50. 0% and 46. 9% respectively）,the difference was statistically significant（ P〈0. 05）. There is no significant difference between the observation group and control group in adverse reactions（ P〈0. 05）. Conclusions Chemotherapy combined Zoledronic acid used in lung cancer and bone metastases can significantly relieve bone pain and other relevant events,improve the patients quality of life and activity ability,and cause less adverse reactions,which is easy to use and is worthy of further clinical application.
出处
《中国肿瘤临床与康复》
2013年第12期1357-1359,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
药物疗法
唑来膦酸
肺肿瘤
骨转移
Drug therapy
Zoledronic acid
Lung neoplasms
Bone metastases
